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exhibit a unique tumor profile. These individuals are predisposed to certain neoplasms, such
as leukemia and other hematological malignancies. However, solid tumors are exceptionally
rare. Central nervous system (CNS) tumors in individuals with Down syndrome have been re-
ported in only a small number of case reports. The majority of these tumors are gliomas
and germ cell tumors. Meningiomas have yet to be reported in Down syndrome. We report
the first case of a meningioma tumor in an individual with Down syndrome. We present a case
of spinal meningioma in a 14-year-old boy with Down syndrome.
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Down syndrome is the most common genetic chromosomal
disorder and occurs in one out of every 700 newborns [1]. It
is well-recognized that individuals with this chromosomal
disorder exhibit a unique tumor profile. These individuals
have a greater risk of developing hematological malig-
nancies such as acute lymphoblastic and acute mega-
karyoblastic leukemias. These tumors are 19-fold more
common among individuals with Down syndrome than in theentre (General Organization), Saudi Arabia. Production and hosting
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1 Sagittal MRI showing a dural-based lesion com-
pressing the spinal cord at the level of T5eT6. The mass is
isointense on T2-weighted (A) and T1-weighted images with
homogenous enhancement following contrast injection (B).
Figure 2 This figure illustrates the arrangement of the cells
in a whirling pattern. The cells have round to oval nuclei and
exhibit nuclear inclusions in some places. Variable numbers of
94 A.J. Jaber, A.M. Alkhaninormal population [2]. Testicular cancer is also markedly
more prevalent among individuals with Down syndrome.
However, other solid tumors are generally uncommon [3,4].
These observations clearly indicate a role of genetic factors
in this altered susceptibility. Such genetic factors remain
poorly understood. Tumors of the central nervous system
(CNS) in individuals with Down syndrome have been re-
ported in the literature in only a few case reports, and the
reported tumors are primarily gliomas and germ cell tu-
mors. Meningiomas have yet to be reported. Here, we
present a case of a 14-year-old boy with Down syndrome
who was diagnosed with a thoracic spine meningioma. This
case report is the first published description of a meningi-
oma in a patient with Down syndrome.
2. Case
A 14-year-old boy known to have trisomy 21 (Down syn-
drome) based on his morphological features presented with
a 2-year history of progressive spastic paraparesis. His
weakness progressed in the 4 months before presentation
at our institute. He became wheelchair-bound with urinary
incontinence. This presentation was initially thought by the
referring hospital to be of musculoskeletal origin and
related to his genetic disorder. He was overweight with a
BMI of 43. He also complained of back pain for the past few
months. The patient and his family denied any history of
trauma, upper limb symptoms, exposure to ionized radia-
tion, or any family history suggestive of neurofibromatosis
disorders or CNS tumors. He went through multiple inpa-
tient and outpatient physiotherapy programs with no clin-
ical improvement, and his symptoms continued to
deteriorate with time. On physical examination, the pa-
tient displayed a significant mental delay for his age. He
was able to communicate with simple dialog only. He had
the classical morphological features of Down syndrome in
his face, neck, hands, and soles. No obvious cutaneous
stigmata suggestive of neurofibromatosis were observed.
Cranial nerve examination revealed no obvious abnormal-
ities. An examination of the upper limbs was within normal
limits. In his lower limbs, he had bilateral spastic weakness
with a motor power of 2e3 on a scale of 5 proximally and 3/
5 distally. He had impairment of all sensory modalities in
the lower limbs with a partial sensory level at T4. Due to his
lower limb weakness, he had been wheelchair-bound for
the last 3 months. His muscles tone was increased with
brisk deep tendon reflexes, a sustained ankle clonus and an
up-going bilateral Babinski’s sign. Chromosomal analysis in
our institute confirmed the karyotype of trisomy 21;47,XY,
þ21. Magnetic resonance Imaging (MRI) of the thoracic
spine revealed an intradural extramedullary dural-based
mass measuring 3 cm in length that was compressing and
displacing the spinal cord anteriorly. The lesion extended
from the vertebral body level of T5eT6. The lesion was
isointense on T1- and T2-weighted images with homogenous
enhancement following intravenous gadolinium injection.
The lesion also had a small dural-based tail [Fig. 1]. The
radiological features were highly suggestive of a spinal
meningioma. MRI of the brain and the rest of the spine
revealed no other lesions. The patient underwent a surgical
intervention that included T5 and T6 bilaterallaminectomies, a midline dural incision and resection of the
dural-based lesion with coagulation of the tumor bed
(Simpson grade II). Intralesional calcifications were noted.
The surgery was uneventful with no intraoperative com-
plications. A few days postoperatively, he experienced a
cerebrospinal fluid leak that was managed with a tempo-
rary lumbar drain. Histopathological study revealed clas-
sical transitional meningothelial cells with the
psammomatous subtype in many areas [Fig. 2]. His physical
evolution was very satisfactory. He exhibited gradualcalcified psammoma bodies were also identified (H&E stain).
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month follow-up evaluation after an outpatient physio-
therapy course, he regained his ability to walk and regained
his bladder control.
3. Discussion
In this case report, we presented a unique case of a me-
ningioma encountered in a boy with Down syndrome (tri-
somy 21 karyotype). This is the first case report of a
meningioma anywhere in the CNS that has been reported in
an individual with this chromosomal abnormality. In-
dividuals with Down syndrome have a unique tumor profile.
In a Japanese population study of more than 112 benign and
malignant tumors in Down syndrome, hematological ma-
lignancies comprised the vast majority and accounted for
87 (78%) of the reviewed cases. Only 3 cases of CNS tumors
were encountered. Two of these cases were germ cell tu-
mors, and one case was reported as unknown [3]. In a
comprehensive review of the literature published in 1998,
Satge´ et al. reviewed all reported tumor cases in Down
syndrome prior to 1998. The review collected 26 CNS tu-
mors that had been reported in the literature. These tu-
mors composed of 9 (35%) gliomas, 6 (23%) germ cell
tumors, and 11 (42%) other different types of CNS tumors,
none of which were meningiomas [4]. We reviewed all
PubMed indexed literature after that date for reports of
CNS tumors associated with Down syndrome and found no
reports of a meningioma tumor.
Evidence explaining the unique tumor profile in Down
syndrome remains sparse. It is believed that mutations in
GATA1 (a gene that encodes an essential transcription
factor for the proper development of hematopoietic
megakaryocytes and other cells) are largely responsible for
the predisposition to transient myeloproliferative disorder
and acute megakaryoblastic leukemia in Down syndrome
[5]. More recent studies have implicated JAK2 mutations in
acute lymphoblastic leukemia associated with Down syn-
drome. In one study, this mutation was present in 18% of
the patients, and it was also correlated with early disease
manifestation [6]. Regarding the notable rarity of solid tu-
mors in Down syndrome, it has been suggested that
increased expressions of genes on chromosome 21 that
encode endogenous angiogenesis inhibitors provides at
least a partial explanation. These antiangiogenic genes
include COL18A, Adam TS-1 and DCR1, all of which have
been reported to be elevated in Down syndrome [7].
Furthermore, the S-100 b protein is also encoded by a gene
localized to chromosome 21. This protein has been shown
to inhibit the growth of human neuroblastoma cell lines and
might be a factor that contributes to the low incidence of
neuroblastoma in particular [8]. Additionally, the merlin/
schwannomin tumor suppressor gene mutation in neurofi-
bromatosis type 2 is known to correlate with the growth of
tumors, such as schwannomas and meningiomas [9]. Such a
gene mutation has yet to be reported in Down syndrome.
In the adult population, meningiomas represent 30% of
all primary CNS tumors [8]. However, in children and ad-
olescents, meningiomas account for less than 5% of all CNS
tumors [10]. Meningiomas in the spine are uncommon and
account for approximately 10% of all meningiomas [9].
Nevertheless, they represent approximately 20% of allintradural spinal tumors and are the second-most common
tumor type after schwannomas [11]. In the medical
literature, approximately 60 cases of spinal meningioma
have been reported in the otherwise normal pediatric
population. A case series of 10 cases of spinal meningi-
omas in children was published from China [12]. A male
predominance is evident in this study (8M-2F), which
contrasts the adult population in which a clear female
predominance with a ratio of more than 3:1 has been
observed [11]. In terms of prognosis, pediatric patients
exhibit an increased rate of recurrence. The rate of
recurrence in the aforementioned Chinese study reached
70% (7/10 patients) [12].
4. Conclusions
Meningiomas are notably rare in Down syndrome. Spinal
meningiomas can be easily missed until late in the course of
the disease. The presence of any atypical presentation such
as upper motor neuron weakness should be taken as in-
dications for radiological investigations to exclude the
possibility of this rare but treatable spinal lesion.
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